Cargando…
Risperidone ISM as a New Option in the Clinical Management of Schizophrenia: A Narrative Review
Antipsychotics are the cornerstone of schizophrenia treatment. Lack of treatment adherence encouraged the development of injectable long-acting antipsychotics. However, second-generation or atypical antipsychotics require a loading dose at the start of treatment and eventually oral supplementation t...
Autor principal: | Álamo, Cecilio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525356/ https://www.ncbi.nlm.nih.gov/pubmed/36048404 http://dx.doi.org/10.1007/s12325-022-02299-8 |
Ejemplares similares
-
Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM(®): results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies
por: Sánchez, Pedro, et al.
Publicado: (2023) -
Clinical utility of the risperidone formulations in the management of schizophrenia
por: Madaan, Vishal, et al.
Publicado: (2011) -
The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study
por: Walling, David P, et al.
Publicado: (2021) -
Efficacy and safety of once-monthly Risperidone ISM(®) in schizophrenic patients with an acute exacerbation
por: Correll, Christoph U., et al.
Publicado: (2020) -
The Steady-State Comparative Bioavailability of Intramuscular Risperidone ISM and Oral Risperidone: An Open-Label, One-Sequence Study [Corrigendum]
Publicado: (2022)